Posted by Michael Wonder on 14 Feb 2020
AbbVie's Skyrizi now listed on the Nova Scotia formulary for the treatment of moderate to severe plaque psoriasis
13 February 2020 - Nova Scotia lists Skyrizi on its provincial formulary effective February 06, 2020.
AbbVie announced today that Nova Scotia has listed Skyrizi (risankizumab) on its provincial formulary for the treatment of moderate to severe plaque psoriasis.
This announcement comes just two months after AbbVie successfully reached an agreement with the pan-Canadian Pharmaceutical Alliance. Nova Scotia joins Ontario, Alberta, Saskatchewan and Quebec in bringing a much-needed treatment to patients living with psoriasis.
